Over the past decade, prostate cancer treatment has increasingly shifted towards less invasive approaches that prioritize preserving patients' quality of life. Among these, various focal therapy ...

The long-term impact of localized prostate cancer treatments on secondary bladder cancer is an important area of study. A recent cohort study by Unger et al. examined secondary bladder cancer ...

Epigenetic changes have been reported to promote the development and progression of prostate cancer (PCa). Compared to normal prostate tissue, tumor samples from patients treated with ...

Early postoperative ambulation shortens the recovery of radical cystectomy (RC). This study aims to evaluate the potential associations between perioperative activity levels, measured by wearable ...

Prostate cancer (PCa) management poses challenges due to treatment-related morbidities associated with conventional therapies. Focal therapy (FT) is emerging as a promising alternative for ...

Prostate Cancer (PrCa) is one of the most common cancers worldwide and causes a significant healthcare burden. Recent predictions estimate the incidence of new cases of PrCa will double from 1.4 ...

The treatment landscape of metastatic clear cell renal cell carcinoma (ccRCC) has rapidly evolved with the approval of multiple immune checkpoint inhibitor (ICI)-based combinations. However, clinical ...

New evidence published in Cell provides insight into the interplay between hypoxia-inducible factor activity and downstream neoantigen production in clear cell renal cell carcinoma (ccRCC). Jiang et ...

Bladder cancer detection relies on invasive cystoscopy and urine cytology, which have several limitations in early diagnosis and frequent monitoring, especially in low-resource settings. A recent ...

TMPRSS2:ERG is the most common gene fusion in prostate cancer. Approximately 140,000 men in the United States are diagnosed with prostate cancer that has the TMPRSS2:ERG gene fusion annually, out of ...

Prostate cancer (PCa) stands as a leading cause of cancer-related mortality among men, with treatment-induced neuroendocrine prostate cancer (NEPC) posing a challenge as an ARPI-resistant subtype. The ...

Cognitive Effects of Abiraterone vs Enzalutamide in Metastatic Castration-Resistant Prostate Cancer - Alicia Morgans ...